Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
Andrew BlauveltApril W ArmstrongRichard G LangleyKurt GebauerDiamant ThaҫiJerry BagelLyn C GuentherCarle F PaulBruce RandazzoSusan FlavinMing-Chun HsuYin YouKristian ReichPublished in: The Journal of dermatological treatment (2021)
Guselkumab treatment provided greater efficacy vs. secukinumab at week 48 in most subpopulations of patients with psoriasis.